Bayer reports phase I results for prostate cancer therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Bayer earnings preview: Recent focus on asundexian momentum ahead of Q4 results
March 3, 2026 6:00 PM ESTBayer AG (OTC: BAYRY) reports fourth-quarter and full-year 2025 results on Wednesday, with analysts more recently focusing on the companys litigation overhang and Asundexian stroke data.
Consensus forecasts point to sales of 11.34 billion for Q4 2025 and 45.48 billion for the full year. Net income is expected to remain negative for 2025, with analysts on average forecasting a 223 million... More



